J Vasc Interv Radiol. 2023 May 12:S1051-0443(23)00342-1. doi: 10.1016/j.jvir.2023.05.010. Online ahead of print.
ABSTRACT
OBJECTIVE: In this systematic review and meta-analysis, we will assess the efficacy and safety of MMA embolization with liquid embolic agents and the outcomes of patients following this procedure.
METHODS: A review of the literature was carried out to identify the studies investigating the efficacy and safety of MMA embolization with liquid embolysate in Chronic Subdural Hematoma (cSDH) patients in PubMed, Scopus, Embase, and Web of science. The keywords liquid embolic agent, middle meningeal artery, cSDH, and embolization and their synonyms were used to build up the search strategy. R statistical software and random-effects model were used for analysis. Heterogeneity was reported as I2 and publication bias was calculated using Egger’s test.
RESULTS: Of the 628 articles retrieved, 14 studies were eligible to be included in this study. A total of data on 276 patients were analyzed. N-butyl cyanoacrylate and Onyx were the most commonly used embolizing agents. This study revealed a pooled mortality rate of 0%(CI:0.00-100%), recurrence and failure rate of 3%(CI:1-10%), reoperation rate of 4%(CI:2-12%), rate of size decrease of 94%(CI:79-98%), success rate of 100%(CI:76-100%) and adverse event rate of 1%(CI:0.00-4%).
CONCLUSIONS: With low mortality, recurrence, reoperation, and adverse event rates and a remarkable decrease in the size of the hematoma, MMA embolization with liquid embolic might be considered a safe and effective treatment option in patients with previously failed surgical intervention and also as an alternative to the conventional treatments.
PMID:37182671 | DOI:10.1016/j.jvir.2023.05.010
